Cargando…
The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?
BACKGROUND: The clinical development of new drugs with radiation appears to be limited. We hypothesised that phase I clinical trials with radiation therapy (RT) are initiated too late into a new drug's lifetime, impeding the ability to complete RT–drug development programmes before patent expir...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183859/ https://www.ncbi.nlm.nih.gov/pubmed/25117813 http://dx.doi.org/10.1038/bjc.2014.448 |
_version_ | 1782337755465908224 |
---|---|
author | Blumenfeld, P Pfeffer, R M Symon, Z Den, R B Dicker, A P Raben, D Lawrence, Y R |
author_facet | Blumenfeld, P Pfeffer, R M Symon, Z Den, R B Dicker, A P Raben, D Lawrence, Y R |
author_sort | Blumenfeld, P |
collection | PubMed |
description | BACKGROUND: The clinical development of new drugs with radiation appears to be limited. We hypothesised that phase I clinical trials with radiation therapy (RT) are initiated too late into a new drug's lifetime, impeding the ability to complete RT–drug development programmes before patent expiration. METHODS: We identified novel drug–radiation phase I combination trials performed between 1980 and 2012 within the PubMed and ClinicalTrials.gov databases. Data gathered for each drug included: date the initial phase I trial with/without RT was opened/published, date of the published positive phase III trials, and patent expiration dates. Lag time was defined as the interval between opening of the phase I trial without RT and the opening of the phase I with RT. Linear regression was used to model how the lag time has changed over time. RESULTS: The median lag time was 6 years. The initial phase I trial with RT was typically published 2 years after the first published positive phase III trial and 11 years before patent expiration. Using a best-fit linear model, lag time decreased from 10 years for phase I trials published in 1990 to 5 years in 2005 (slope significantly non-zero, P<0.001). CONCLUSIONS: Clinical drug development with RT commences late in the life cycle of anti-cancer agents. Taking into account the additional time required for late-phase clinical trials, the delay in initiating clinical testing of drug–RT combinations discourages drug companies from further pursuing RT-based development. Encouragingly, lag time appears to be decreasing. Further reduction in lag time may accelerate RT-based drug development, potentially improving patient outcomes. |
format | Online Article Text |
id | pubmed-4183859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-41838592015-09-23 The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? Blumenfeld, P Pfeffer, R M Symon, Z Den, R B Dicker, A P Raben, D Lawrence, Y R Br J Cancer Clinical Study BACKGROUND: The clinical development of new drugs with radiation appears to be limited. We hypothesised that phase I clinical trials with radiation therapy (RT) are initiated too late into a new drug's lifetime, impeding the ability to complete RT–drug development programmes before patent expiration. METHODS: We identified novel drug–radiation phase I combination trials performed between 1980 and 2012 within the PubMed and ClinicalTrials.gov databases. Data gathered for each drug included: date the initial phase I trial with/without RT was opened/published, date of the published positive phase III trials, and patent expiration dates. Lag time was defined as the interval between opening of the phase I trial without RT and the opening of the phase I with RT. Linear regression was used to model how the lag time has changed over time. RESULTS: The median lag time was 6 years. The initial phase I trial with RT was typically published 2 years after the first published positive phase III trial and 11 years before patent expiration. Using a best-fit linear model, lag time decreased from 10 years for phase I trials published in 1990 to 5 years in 2005 (slope significantly non-zero, P<0.001). CONCLUSIONS: Clinical drug development with RT commences late in the life cycle of anti-cancer agents. Taking into account the additional time required for late-phase clinical trials, the delay in initiating clinical testing of drug–RT combinations discourages drug companies from further pursuing RT-based development. Encouragingly, lag time appears to be decreasing. Further reduction in lag time may accelerate RT-based drug development, potentially improving patient outcomes. Nature Publishing Group 2014-09-23 2014-08-12 /pmc/articles/PMC4183859/ /pubmed/25117813 http://dx.doi.org/10.1038/bjc.2014.448 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Clinical Study Blumenfeld, P Pfeffer, R M Symon, Z Den, R B Dicker, A P Raben, D Lawrence, Y R The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? |
title | The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? |
title_full | The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? |
title_fullStr | The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? |
title_full_unstemmed | The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? |
title_short | The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? |
title_sort | lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183859/ https://www.ncbi.nlm.nih.gov/pubmed/25117813 http://dx.doi.org/10.1038/bjc.2014.448 |
work_keys_str_mv | AT blumenfeldp thelagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT pfefferrm thelagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT symonz thelagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT denrb thelagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT dickerap thelagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT rabend thelagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT lawrenceyr thelagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT blumenfeldp lagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT pfefferrm lagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT symonz lagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT denrb lagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT dickerap lagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT rabend lagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress AT lawrenceyr lagtimeininitiatingclinicaltestingofnewdrugsincombinationwithradiationtherapyasignificantbarriertoprogress |